Researchers had touted the long-awaited rotigotine (Neupro) skin patch for its consistent delivery of a once-daily dose directly into the blood stream. The patch was supposed to be particularly beneficial for early-stage Parkinson's disease. Impatiently awaiting FDA approval, I was about ready to go overseas to get it when my neurologist announced free samples had arrived. I was optimistic that my chronic symptoms would stabilize or abate.
The insert's disclaimers were the usual: may cause hallucinations, sleepiness, edema, etc. Nothing new. To mitigate sensitivity to the adhesive, one-inch square, patients are advised to rotate the location of the patch daily and avoid creases in the skin's surface.
But as I titrated to the next stages, the size of the patch increased to two- and then three-inch squares, which became impossible to camouflage. Because this “appliqué” broadcasts your Parkinson's disease diagnosis, it would be great if the manufacturer could spruce it up by offering a choice of skin tones, colors, or motifs.